

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : A61K 31/57		A1	(11) International Publication Number: WO 98/50042 (43) International Publication Date: 12 November 1998 (12.11.98)
(21) International Application Number: PCT/US98/08456		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(22) International Filing Date: 28 April 1998 (28.04.98)		(30) Priority Data: 08/850,567 2 May 1997 (02.05.97) US	
(71) Applicant: AMERICAN HOME PRODUCTS CORPORATION [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US).		(72) Inventors: KAGAN, Michael, Z.; 4 Mackenzie Lane, Plainsboro, NJ 08536 (US). SHAH, Syed, Muzafer; 13 Yvette Drive, East Hanover, NJ 07936 (US).	
(74) Agents: ALICE, Ronald, W.; American Home Products Corporation, Patent Law Dept. - 2B, One Campus Drive, Parsippany, NJ 07054 (US) et al.		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: PREGNAN-3-OL-20-ONES			
(57) Abstract <p>This invention provides a method of providing progestational therapy to a mammal in need thereof which comprises administering a progestationally effective amount of a pharmaceutically acceptable salt of 5α-pregnan-3β-ol-20-one 3-sulfate ester to said mammal.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NB	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

- 1 -

PREGNAN-3-OL-20-ONES

BACKGROUND OF THE INVENTION

5

The use of naturally occurring estrogenic compositions of substantial purity and low toxicity such as PREMARIN (conjugated equine estrogens) has become a preferred medical treatment for alleviating the symptoms of menopausal syndrome, osteoporosis/osteopenia in estrogen deficient women and in other hormone related 10 disorders. The estrogenic components of the naturally occurring estrogenic compositions have been generally identified as sulfate esters of estrone, equilin, equilenin, 17- β -estradiol, dihydroequilenin and 17- β -dihydroequilenin (U.S. Patent 2,834,712). The estrogenic compositions are usually buffered or stabilized with alkali metal salts of organic or inorganic acids at a substantially neutral pH of 15 about 6.5 to 7.5. Urea has also been used as a stabilizer (U.S. 3,608,077). The incorporation of antioxidants to stabilize synthetic conjugated estrogens and the failure of pH control with tris(hydroxymethyl)aminomethane (TRIS) to prevent hydrolysis is discussed in U.S. 4,154,820.

One of the compounds described herein, 5 α -pregnan-3 β -ol-20-one 3-sulfate 20 ester sodium salt is a minor component of PREMARIN (conjugated equine estrogens), and is also commercially available.

DESCRIPTION OF THE INVENTION

25

In accordance with this invention, there is providing progestational therapy to a mammal in need thereof, which comprises administering a pharmaceutically acceptable salt of 5 α -pregnan-3 β -ol-20-one 3-sulfate ester to said mammal. This invention also provides a method of providing progestational therapy to a mammal in need thereof, which comprises administering a composition of matter consisting essentially of a 30 pharmaceutically acceptable salt of 5 α -pregnan-3 β -ol-20-one 3-sulfate ester to said mammal.

35

Pharmaceutically acceptable salts of 5 α -pregnan-3 β -ol-20-one 3-sulfate ester include, but are not limited to, the alkali metal salts, alkaline earth metal salts, ammonium salts, alkylammonium salts containing 1-6 carbon atoms or dialkylammonium salts containing 1-6 carbon atoms in each alkyl group,

- 2 -

trialkylammonium salts containing 1-6 carbon atoms in each alkyl group and tetraalkylammonium salts containing 1-6 carbon atoms in each alkyl group.

Alkali metal salts include sodium and potassium salts, particularly preferred are 5 sodium salts. Alkaline earth metal salts include calcium and magnesium salts. Suitable alkyl groups include methyl, ethyl, propyl, butyl, pentyl and hexyl, preferred alkyl groups being methyl and ethyl. Where more than one alkyl group is present the groups may be the same or different. Preferred trialkylammonium salts are trimethylammonium salts and triethylammonium salts.

10

The present invention further provides compositions comprising pharmaceutically acceptable salt of 5α -pregnan-3 β -ol-20-one 3-sulfate ester. In particular it provides compositions comprising at least 1% of pharmaceutically acceptable salt of 5α -pregnan-3 β -ol-20-one 3-sulfate ester. One aspect of the present 15 invention provides compositions wherein the only progestational agent is a pharmaceutically acceptable salt of 5α -pregnan-3 β -ol-20-one 3-sulfate ester. Embodiments of the present invention include compositions wherein the only active compound is pharmaceutically acceptable salt of 5α -pregnan-3 β -ol-20-one 3-sulfate ester. In these embodiments other excipients and carriers may be included but no 20 further active materials are included.

The present invention also provides a process for the preparation of a pharmaceutically acceptable salt of 5α -pregnan-3 β -ol-20-one 3-sulfate ester which comprises:

25 a) converting 5α -pregnan-3 β -ol-20-one 3-sulfate ester to a pharmaceutically acceptable salt or
b) converting a pharmaceutically acceptable salt of 5α -pregnan-3 β -ol-20-one 3-sulfate ester to a different pharmaceutically acceptable salt of 5α -pregnan-3 β -ol-20-one 30 3-sulfate ester.

5α -pregnan-3 β -ol-20-one 3-sulfate esters may be converted to pharmaceutically acceptable salts by neutralising the acid with an appropriate base, e.g. with an alkali metal carbonate, an alkaline earth metal carbonate or a primary, secondary, tertiary or 35 quaternary amine carbonate. Alkali metal or alkaline earth metal salts may be prepared

- 3 -

by using the appropriate alkali metal hydride e.g. sodium hydride, potassium hydride or lithium hydride.

A pharmaceutically acceptable salt of 5α -pregnan-3 β -ol-20-one 3-sulfate ester may be
5 converted to a different pharmaceutically acceptable salt of 5α -pregnan-3 β -ol-20-one 3-sulfate ester by displacement, by using an ion exchange resin or by double decomposition (metastasis). Displacement of a weak base with a stronger one may be utilised to convert, e.g. an amine salt to an alkali metal salt or an alkaline earth metal salt using an appropriate base, e.g. a hydroxide. For example a trialkylamine salt such as a
10 triethylamine salt may be converted to an alkali metal salt such as a sodium salt by treating it with an alkali metal hydroxide such as aqueous sodium hydroxide. The displacement may be carried out using an ion exchange resin. Alternatively one salt may be converted to another by double decomposition, e.g. an alkaline earth metal salt such as the calcium salt may be replaced with an alkali metal salt. E.g. the calcium salt
15 of 5α -pregnan-3 β -ol-20-one 3-sulfate ester may be dissolved in water followed by the addition of e.g. sodium carbonate. Insoluble calcium carbonate would then precipitate out to provide the sodium salt of 5α -pregnan-3 β -ol-20-one 3-sulfate ester.

A pharmaceutically acceptable salt of 5α -pregnan-3 β -ol-20-one 3-sulfate ester may be
20 prepared by directly converting 5α -pregnan-3 β -ol-20-one to a pharmaceutically acceptable salt of 5α -pregnan-3 β -ol-20-one 3-sulfate ester. This may be performed by reacting it with the appropriate aminesulfurtrioxide complex, e.g. by reacting it with a trialkylaminesulfurtrioxide (such as triethylaminesulfurtrioxide complex) to provide the corresponding trialkylamine salt (such as the triethylamine salt). If desired the salt may
25 then be converted to another salt of the invention as described above. Alkali metal or alkaline earth metal salts may be prepared by treating 5α -pregnan-3 β -ol-20-one with the appropriate alkali metal hydride e.g. sodium hydride, potassium hydride or lithium hydride to produce the corresponding alkoxide *in situ* and then adding a trialkylaminesulfurtrioxide (such as triethylaminesulfurtrioxide complex) to provide the
30 corresponding trialkylamine salt (such as the triethylamine salt). If desired the salt may then be converted to another salt of the invention as described above.

The present invention also provides pharmaceutically acceptable salts of 5α -pregnan-3 β -ol-20-one 3-sulfate ester prepared by a chemical process, particularly those prepared
35 according to the processes described above. The invention also provides

pharmaceutically acceptable salts of 5α -pregnan- 3β -ol-20-one 3-sulfate ester obtainable by such processes.

5 The compounds of this invention can be prepared from readily available starting materials using standard literature techniques or can be purchased, as with 5α -pregnan- 3β -ol-20-one 3-sulfate ester sodium salt.

10 The progestational activity of a representative compound of this invention (5α -pregnan- 3β -ol-20-one 3-sulfate ester sodium salt) was evaluated in an in vitro standard pharmacological test procedure. The procedure used and results obtained are briefly described below.

15 The results of these standard pharmacological test procedures demonstrate that the compounds of this invention are progestational. In this test procedure, the progestational activity of a compound is quantified based on its stimulation of alkaline phosphatase enzyme activity in T47D cells, a human breast cancer cell line which expresses high levels of progesterone receptors. This is a well established test procedure in which both the progestin receptors and the response stimulated by activated progestin receptors are endogenous to the cells. Cells are pre-conditioned in 20 low serum medium for one day and then treated with test compounds. Alkaline phosphatase activity is measured 24 hr after treatment. Reference progestins, such as progesterone and medroxyprogesterone acetate, induce a 30 - 60 fold induction of alkaline phosphatase requiring only low nanomolar concentrations for activity. The alkaline phosphatase activity induced by progestins is blocked or inhibited by progestin 25 receptor antagonists such as RU486 indicating the specificity of the response. When evaluated in this test procedure, 5α -pregnan- 3β -ol-20-one 3-sulfate ester sodium salt, had an IC_{50} of 5×10^{-6} demonstrating progestational activity.

30 The neuroprotective and cognition enhancing effects of the compounds of this invention were evaluated in an in vitro standard pharmacological test procedure which measured the effects of 5α -pregnan- 3β -ol-20-one 3-sulfate ester sodium salt, as a representative compound of this invention, on calcium and potassium channel currents. Briefly, the following procedure was used.

35 Whole cell recording techniques were used to record calcium and potassium currents from cultured hippocampal neurons. The compounds to be evaluated were made fresh each day in a 400 μ M ethanol stock solution. The test compounds were

- 5 -

diluted in saline to obtain a final concentration of 2 μ M. The amplitude of calcium or potassium currents in control, test compound, and washout solutions was measured from at least 10 current traces for each condition. To compensate for rundown of the calcium current with time, control and washout currents were averaged. The current 5 amplitude with drug was divided by the averaged control and washout current to determine the percent change. The means, standard deviations and errors for each test compound were calculated and significance from control was determined using the paired T-Test. 5 α -Pregnan-3 β ,20 β -diol enhanced increased potassium channel currents versus control by 21.76 \pm 2.40 % (p = 0.0006), indicating that 5 α -pregnan-3 β ,20 β -diol hyperpolarizes neurons, thereby allowing them to respond more readily to other 10 stimuli. Calcium channel currents were significantly decreased (p = 0.044) from control decrease by 4.64 \pm 1.64 % versus control) demonstrating the neuroprotective effects of 5 α -pregnan-3 β -ol-20-one 3-sulfate ester sodium salt,. These results show that the compounds of this invention are useful as neuroprotective agents, in protecting 15 against epileptic seizures, and in cognition enhancement.

The compounds of this invention are progestational agents. Based on the results obtained in the standard pharmacological test procedures, the compounds of the invention are useful as oral contraceptives (male and female), in hormone replacement 20 therapy (particularly when combined with an estrogen), in the treatment of endometriosis luteal phase defects, benign breast and prostatic diseases and prostatic and endometrial cancers. The compounds of this invention are also useful in protecting against epileptic seizures, in cognition enhancement, in treating Alzheimer's disease, dementias, vasomotor symptoms related to menopause, and other central 25 nervous system disorders. The compounds of this invention are further useful in stimulating erythropoiesis.

The compounds of this invention can be used alone as a sole therapeutic agent or can be used in combination with other agents, such as other estrogens, progestins, 30 or androgens.

The compounds of this invention can be formulated neat or with a pharmaceutical carrier for administration, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration and 35 standard pharmacological practice. The pharmaceutical carrier may be solid or liquid.

A solid carrier can include one or more substances which may also act as flavoring agents, lubricants, solubilizers, suspending agents, fillers, glidants, compression aids, binders or tablet-disintegrating agents; it can also be an encapsulating material. In powders, the carrier is a finely divided solid which is in admixture with the 5 finely divided active ingredient. In tablets, the active ingredient is mixed with a carrier having the necessary compression properties in suitable proportions and compacted in the shape and size desired. The powders and tablets preferably contain up to 99% of the active ingredient. Suitable solid carriers include, for example, calcium phosphate, magnesium stearate, talc, sugars, lactose, dextrin, starch, gelatin, cellulose, methyl 10 cellulose, sodium carboxymethyl cellulose, polyvinylpyrrolidine, low melting waxes and ion exchange resins.

Liquid carriers are used in preparing solutions, suspensions, emulsions, syrups, elixirs and pressurized compositions. The active ingredient can be dissolved or suspended in a pharmaceutically acceptable liquid carrier such as water, an organic 15 solvent, a mixture of both or pharmaceutically acceptable oils or fats. The liquid carrier can contain other suitable pharmaceutical additives such as solubilizers, emulsifiers, buffers, preservatives, sweeteners, flavoring agents, suspending agents, thickening agents, colors, viscosity regulators, stabilizers or osmo-regulators. Suitable examples of liquid carriers for oral and parenteral administration include water (partially 20 containing additives as above, e.g. cellulose derivatives, preferably sodium carboxymethyl cellulose solution), alcohols (including monohydric alcohols and polyhydric alcohols, e.g. glycols) and their derivatives, lethicins, and oils (e.g. fractionated coconut oil and arachis oil). For parenteral administration, the carrier can also be an oily ester such as ethyl oleate and isopropyl myristate. Sterile liquid carriers 25 are useful in sterile liquid form compositions for parenteral administration. The liquid carrier for pressurized compositions can be halogenated hydrocarbon or other pharmaceutically acceptable propellant.

Liquid pharmaceutical compositions which are sterile solutions or suspensions can be utilized by, for example, intramuscular, intraperitoneal or subcutaneous 30 injection. Sterile solutions can also be administered intravenously. The compounds of this invention can also be administered orally either in liquid or solid composition form.

The compounds of this invention may be administered rectally or vaginally in the form of a conventional suppository. For administration by intranasal or intrabronchial inhalation or insufflation, the compounds of this invention may be 35 formulated into an aqueous or partially aqueous solution, which can then be utilized in the form of an aerosol. The compounds of this invention may also be administered

transdermally through the use of a transdermal patch containing the active compound and a carrier that is inert to the active compound, is non toxic to the skin, and allows delivery of the agent for systemic absorption into the blood stream via the skin. The carrier may take any number of forms such as creams and ointments, pastes, gels, and 5 occlusive devices. The creams and ointments may be viscous liquid or semisolid emulsions of either the oil-in-water or water-in-oil type. Pastes comprised of absorptive powders dispersed in petroleum or hydrophilic petroleum containing the active ingredient may also be suitable. A variety of occlusive devices may be used to release the active ingredient into the blood stream such as a semipermeable membrane 10 covering a reservoir containing the active ingredient with or without a carrier, or a matrix containing the active ingredient. Other occlusive devices are known in the literature.

The dosage requirements vary with the particular compositions employed, the route of administration, the severity of the symptoms presented and the particular 15 subject being treated. Based on the results obtained in the standard pharmacological test procedures, projected daily dosages of active compound would be 0.02 $\mu\text{g}/\text{kg}$ - 750 $\mu\text{g}/\text{kg}$. Treatment will generally be initiated with small dosages less than the optimum dose of the compound. Thereafter the dosage is increased until the optimum effect under the circumstances is reached; precise dosages for oral, parenteral, nasal, or 20 intrabronchial administration will be determined by the administering physician based on experience with the individual subject treated. Preferably, the pharmaceutical composition is in unit dosage form, e.g. as tablets or capsules. In such form, the composition is sub-divided in unit dose containing appropriate quantities of the active ingredient; the unit dosage forms can be packaged compositions, for example, packeted 25 powders, vials, ampoules, prefilled syringes or sachets containing liquids. The unit dosage form can be, for example, a capsule or tablet itself, or it can be the appropriate number of any such compositions in package form.

WHAT IS CLAIMED IS:

1. A method of providing progestational therapy to a mammal in need thereof which comprises administering a progestationally effective amount of a pharmaceutically acceptable salt of 5α -pregnan-3 β -ol-20-one 3-sulfate ester to said mammal to said mammal.
2. The method according to claim 1, wherein the pharmaceutically acceptable salt of the 3-sulfate ester is an alkali metal salt, alkaline earth metal salt, ammonium salt, alkylammonium salts containing 1-6 carbon atoms or dialkylammonium salts containing 1-6 carbon atoms in each alkyl group, trialkylammonium salts containing 1-6 carbon atoms in each alkyl group and tetraalkylammonium salts containing 1-6 carbon atoms in each alkyl group.
3. A method of treating or inhibiting cancers, central nervous system disorders, dementias, or Alzheimer's disease in a mammal in need thereof, which comprises administering a progestationally effective amount of a pharmaceutically acceptable salt of 5α -pregnan-3 β -ol-20-one 3-sulfate ester to said mammal to said mammal.
4. The method according to claim 3, wherein the pharmaceutically acceptable salt of the 3-sulfate ester is an alkali metal salt, alkaline earth metal salt, ammonium salt, alkylammonium salts containing 1-6 carbon atoms or dialkylammonium salts containing 1-6 carbon atoms in each alkyl group, trialkylammonium salts containing 1-6 carbon atoms in each alkyl group and tetraalkylammonium salts containing 1-6 carbon atoms in each alkyl group.
5. A method of providing progestational therapy to a mammal in need thereof which comprises administering a progestationally effective amount of a composition of matter consisting essentially of a pharmaceutically acceptable salt of 5α -pregnan-3 β -ol-20-one 3-sulfate ester to said mammal to said mammal.
6. The method according to claim 5, wherein the pharmaceutically acceptable salt of the 3-sulfate ester is an alkali metal salt, alkaline earth metal salt, ammonium salt, alkylammonium salts containing 1-6 carbon atoms or dialkylammonium salts containing 1-6 carbon atoms in each alkyl group, trialkylammonium salts containing 1-6 carbon atoms in each alkyl group and tetraalkylammonium salts containing 1-6 carbon atoms in each alkyl group.

7. A method of treating or inhibiting cancers, central nervous system disorders, dementias, or Alzheimer's disease in a mammal in need thereof, which comprises administering a progestationally effective amount of a composition of matter consisting
5 essentially of a pharmaceutically acceptable salt of 5α -pregnan-3 β -ol-20-one 3-sulfate ester to said mammal to said mammal.

8. The method according to claim 7, wherein the pharmaceutically acceptable salt of the 3-sulfate ester is an alkali metal salt, alkaline earth metal salt, ammonium salt,
10 alkylammonium salts containing 1-6 carbon atoms or dialkylammonium salts containing 1-6 carbon atoms in each alkyl group, trialkylammonium salts containing 1-6 carbon atoms in each alkyl group and tetraalkylammonium salts containing 1-6 carbon atoms in each alkyl group.

15 9. A method of providing cognition enhancement to a mammal in need thereof which comprises administering a cognition enhancement effective amount of a pharmaceutically acceptable salt of 5α -pregnan-3 β -ol-20-one 3-sulfate ester to said mammal to said mammal.

20 10. The method according to claim 9, wherein the pharmaceutically acceptable salt of the 3-sulfate ester is an alkali metal salt, alkaline earth metal salt, ammonium salt, alkylammonium salts containing 1-6 carbon atoms or dialkylammonium salts containing 1-6 carbon atoms in each alkyl group, trialkylammonium salts containing 1-6 carbon atoms in each alkyl group and tetraalkylammonium salts containing 1-6 carbon atoms in
25 each alkyl group.

11. Use of a pharmaceutically acceptable salt of 5α -pregnan-3 β -ol-20-one 3-sulfate ester as a medicament.

30 12. Use of a pharmaceutically acceptable salt of 5α -pregnan-3 β -ol-20-one 3-sulfate ester in the preparation of a medicament for:

- a) providing progestational therapy,
- b) treating or inhibiting cancers, central nervous system disorders, dementias, or Alzheimer's disease or
- 35 c) providing cognition enhancement

to a mammal in need thereof.

- 10 -

13. A process for the preparation of a pharmaceutically acceptable salt of 5α -pregnan-3 β -ol-20-one 3-sulfate ester which comprises:

5 a) converting 5α -pregnan-3 β -ol-20-one 3-sulfate ester to a pharmaceutically acceptable salt or

10 b) converting a pharmaceutically acceptable salt of 5α -pregnan-3 β -ol-20-one 3-sulfate ester to a different pharmaceutically acceptable salt of 5α -pregnan-3 β -ol-20-one 3-sulfate ester.

14. A process for the preparation of a pharmaceutically acceptable salt of 5α -pregnan-3 β -ol-20-one 3-sulfate ester which comprises the direct conversion of 5α -pregnan-3 β -ol-20-one.

15